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Sample mislabeling is a pervasive problem in biomedical
research, especially large-scale multi-omics studies,
contributing to errors and leading to false conclusions. The
Food and Drug Administration (FDA) and the National
Cancer Institute Clinical Proteomic Tumor Analysis
Consortium (NCI-CPTA) have launched a data science
challenge to address this problem.
We developed a novel machine learning based approach
that combines traditional machine learning with learning
from cancer genomics literature to identify mislabeled
tumors in the NCI-CPTA Multi-omics Mislabeling Challenge.
We achieved a sensitivity of 0.833 and a specificity of 0.853




A key aspect of the challenge was identifying the correct microsatellite
instability (MSI) status for patients using only proteomic data. Recent
work shows that the mutator phenotype caused by mismatch repair
deficiency (MMRd) exerts broad and predictable effects on the
transcriptome, allowing RNA expression to predict the mutator
phenotype with high specificity and sensitivity. As an extension of this
work, our hypothesis was that high MSI will lead to a greater variance
in protein expression in exons with accumulating SNVs. We applied the
following formal hypothesis to each protein
Methods
Conclusions
When comparing the prediction of sex and MSI by our
model to the actual prediction, any mismatches were
determined to be mislabeled data. Results on the unseen
test set yielded sensitivity of 0.833 and a specificity of
0.853. These results demonstrate the potential of machine
learning-based techniques to predict sample mislabeling.
The next steps would be to test the current model on real
tumor research data and then improve the model with a
larger training data of naturally occurring mislabels. With
larger sample sizes more advanced techniques can be
applied, such as neural networks and random forest to
improve performance and generalizability and, ultimately,
reduce the quantity of human errors in research.
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To create a model to identify mislabeled samples, we used
proteomics data to predict both the correct sex and MSI
and compare predictions to the the given data. This would
identify mislabeled instances of sample swapping and,
potentially, duplication and shifting as well.
Sex mislabeling was predicted using genes unique to the y
chromosome and associated with cancer. We turned these
genes into dummy variables (present/not present) and
evaluated each protein’s predictive value using kappa
statistics. Two genes far out-performed the rest, DDX3Y and
RPS4Y1, which together gave us the gender prediction in
our test set.
MSI was predicting by applying dimensionality reduction
and a logistic regression classifier. First, we conducted an F-
test with an adjusted p-threshold of 0.05 to identify 31
proteins that are dysregulated in unstable tumor genomes
(high MSI) compared to stable tumor genomes (low MSI).
An additional 31 proteins in our dataset were identified in
medical literature to be associated with MSI and were
included in our dataset. We used these 62 proteins in a
logistic regression model to predict MSI.
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H0: σ2low MSI = σ2high MSI
Ha: σ2low MSI ≠ σ2high MSI
To test this hypothesis we calculated the F-statistic for each protein, 
which is a ratio of the expression variance
Χ ~ F-distributed, where:
𝑋𝑋 = 𝑠𝑠2ℎ𝑖𝑖𝑖𝑖ℎ 𝑀𝑀𝑀𝑀𝑀𝑀𝜎𝜎2ℎ𝑖𝑖𝑖𝑖ℎ 𝑀𝑀𝑀𝑀𝑀𝑀
𝑠𝑠2𝑙𝑙𝑝𝑝𝑙𝑙 𝑀𝑀𝑀𝑀𝑀𝑀
𝜎𝜎2𝑙𝑙𝑝𝑝𝑙𝑙 𝑀𝑀𝑀𝑀𝑀𝑀
At an adjusted p-value threshold of 0.05, we discovered 31 proteins 
from the total set of 4,117 for which we rejected the null hypothesis. 
In addition, we did a literature search that yielded an additional 31 
proteins strongly associated with MMR dysfunction. In total, we used 
62 protein expression profiles to build a logistic regression model 
predicting the MSI status for unlabeled patients. 
Determining Sex
We examined several proteins coded on the Y-chromosome to identify
men from women, since women should have zero expression of these
genes. However, we found these to have high specificity but low
sensitivity due to incomplete measurements in men. We decided to look
for the genes with the highest prediction value by calculating Cohen’s
kappa coefficient for these sex-linked genes:
𝜅𝜅 = 𝑝𝑝𝑝𝑝 − 𝑝𝑝𝑝𝑝1 − 𝑝𝑝𝑝𝑝
Where po is the prediction accuracy of the protein, and pe is the
hypothetical accuracy due to random chance. The two highest scoring
proteins were those coded by DDX3Y and RPS4Y1. We used both in order
to distinguish sex in the test data.
Results
Data
Data was provided by the NCI-CPTA via the Precision FDA
website. The training and test set both contained 80 tumor
samples, each with information on the patient sex (M/F),
MSI status (high/low), proteomics (expression level of 4119
proteins), and mislabeling status. Mislabeling status on the
test was withheld until after Precision FDA challenge had
ended.
Challenge organizers introduced mislabeling errors to
approximately 15% of the data in a manner to simulate
human errors. For proteomics data, this includes
duplication errors (B –> A’, where A’ is a duplicate of A),
sample swapping (A <-> B), and sample shifting (A -> B, B ->
C, C -> D). For clinical data, sample swapping (A <-> B) was
introduced between gender inconsistent samples.
